Malcolm L. MacGregor | January 27, 2026 | Miscellaneous

Ongoing Ozempic Lawsuits: What You Need to Know

Thousands of lawsuits have been filed against Novo Nordisk and Eli Lilly, the manufacturers of semaglutide weight-loss medications commonly referred to as “GLP-1s”. This class of medications includes Ozempic, Wegovy, and Rybelsus, manufactured by the Novo Nordisk defendants, and Trulicity and Mounjaro, manufactured by Eli Lilly and Company.

Plaintiffs allege these medications caused serious gastrointestinal injuries and that they did not receive adequate warnings. If you suffered severe injuries from GLP-1s, understanding the current litigation may help you evaluate your options and whether you may be entitled to pursue economic and non-economic damages in court.

What Is the Ozempic Multidistrict Litigation?

MDL 3094 (often referred to as the Ozempic MDL) is the consolidated federal court proceeding in the Eastern District of Pennsylvania where thousands of lawsuits related to glucagon-like peptide-1 receptor agonists (“GLP-1 RAs”) are centralized. These medications were originally developed for diabetes, but are widely used for weight loss.

As of January 2026, over 3,000 cases have been consolidated in the MDL. All cases remain separate and will be tried separately. However, decisions on key legal issues can influence the outcomes of all cases.

Injuries Alleged in Ozempic Lawsuits

Plaintiffs in the Ozempic MDL have reported severe conditions and side effects associated with using GLP-1s. 

These conditions dramatically affect the quality of life and include:

  • Patients unable to eat regular meals
  • Losing careers because of constant illness
  • Experiencing social isolation
  • Requiring feeding tubes or total parenteral nutrition (IV feeding)
  • Enduring chronic pain and digestive distress that disrupts every aspect of daily living

These severe conditions include, but are not limited to, the following specific diagnoses being claimed in the lawsuits.

Gastroparesis

Patients have also reported severe and chronic nausea, persistent vomiting, feeling full after eating very little, abdominal pain, bloating, and acid reflux. In severe cases, gastroparesis leads to malnutrition, dangerous weight loss, dehydration requiring hospitalization, and inability to maintain employment or normal daily activities.

Ileus

Ileus is the temporary paralysis or severe slowing of the intestines that prevents the normal movement of digestive contents. Symptoms include inability to pass stool or gas, severe abdominal distension and pain, vomiting, nausea, and the absence of normal bowel sounds. Ileus can be life-threatening and often requires hospitalization.

Bowel Obstruction

A partial or complete blockage of the small or large intestine, which can result from severe gastroparesis or ileus, or from other GLP-1-related digestive complications. Complete bowel obstruction is a medical emergency that can lead to bowel perforation, sepsis, and wrongful death if not treated promptly with surgery.

Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

NAION can result in sudden vision loss caused by a reduction of blood flow to the optic nerve. This condition can result in permanent vision impairment or blindness. Research published in mid-2024 suggested a potential association between GLP-1 medications and an increased risk of NAION, prompting additional lawsuits focused specifically on vision-loss claims.

FDA Warnings and Label Updates

The FDA required manufacturers of GLP-1 receptor agonists to update drug labels to include a warning about Ileus in September 2023. This update followed the agency’s review of post-market reports of intestinal blockage events in patients taking these medications.

Questions remain about whether the risk of gastroparesis is adequately communicated. Drug labels mention gastrointestinal side effects. However, plaintiffs argue that the warnings fail to adequately convey the risk of severe, potentially permanent gastroparesis. They contend that patients and prescribers were not informed that routine side effects could progress to debilitating chronic conditions requiring hospitalization and long-term medical intervention.

The FDA warning history could apply to the Ozempic litigation. Plaintiffs argue that manufacturers had access to adverse event reports and clinical data showing serious gastrointestinal complications and still failed to provide adequate warnings until the FDA mandated label changes.

Have There Been Any Settlements?

Novo Nordisk and Eli Lilly continue to vigorously contest liability. Plaintiffs’ claims of negligence allege that the manufacturers failed to adequately warn consumers and healthcare providers about the risk of severe gastrointestinal injuries. The defendants maintain their medications are safe and effective when used as directed. They also allege that the product warnings adequately disclose known risks.

As of January 2026, no global settlements have been reached. 

Who May Qualify to File a Claim

Each case must be evaluated individually to determine if someone may qualify for a claim. 

However, the general criteria required include:

  • Used Ozempic or other GLP-1 drug
  • Developed gastroparesis, ileus, or severe GI complications requiring hospitalization or extended treatment
  • Medical documentation of a diagnosis and treatment
  • Evidence of causation between the medication and the condition

The specific details of your situation will be crucial in assessing your eligibility. Consultation with an attorney is recommended to assess the specifics of your situation and navigate the personal injury process.

Contact McDonald & MacGregor LLC Today for a Free Consultation With a Scranton Personal Injury Attorney

Contact McDonald & MacGregor, LLC, in Scranton to discuss a potential Ozempic injury claim. We can provide additional information to assist you in determining whether you may be eligible to file an Ozempic lawsuit.

Schedule a free case evaluation with our team today. We proudly serve Scranton, Wilkes-Barre, Hazleton, Luzerne County, Lackawanna County, and surrounding areas.

McDonald & MacGregor, LLC
220 Penn Ave Suite 320, Scranton, PA 18503
(570) 209-7062